These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23921283)

  • 1. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
    Dooley JM; Bobbitt SA; Cummings EA
    Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
    Biggar WD; Harris VA; Eliasoph L; Alman B
    Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deflazacort treatment of Duchenne muscular dystrophy.
    Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
    J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
    McAdam LC; Mayo AL; Alman BA; Biggar WD
    Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
    Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
    Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vertebral compression in Duchenne muscular dystrophy following deflazacort.
    Talim B; Malaguti C; Gnudi S; Politano L; Merlini L
    Neuromuscul Disord; 2002 Mar; 12(3):294-5. PubMed ID: 11801403
    [No Abstract]   [Full Text] [Related]  

  • 10. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
    Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
    Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
    [No Abstract]   [Full Text] [Related]  

  • 11. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
    Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
    Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL; Craven BC; McAdam LC; Biggar WD
    Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
    Rice ML; Wong B; Horn PS; Yang MB
    J AAPOS; 2018 Jun; 22(3):192-196. PubMed ID: 29733899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
    Lee SL; Lim A; Munns C; Simm PJ; Zacharin M
    Horm Res Paediatr; 2020; 93(2):108-118. PubMed ID: 32610327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
    Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
    Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
    Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
    Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid-Associated Demise of a Patient With Duchenne Muscular Dystrophy.
    Brahmsteadt AE; Bach JR; Pishdad R; Cespedes L; Pierucci P
    Am J Phys Med Rehabil; 2020 Dec; 99(12):e146-e148. PubMed ID: 32195738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.